Boehringer Ingelheim Venture Fund (BIVF) and Gruenderfonds Ruhr have co-led a €12m series-A for biotechnology company Abalos Therapeutics.
Exit of UK-based software provider set to generate 40%-plus IRR; Baird advised on auction
New partner Sascha Konwalski joins Frankfurt office; US law firm to open new offices in Europe
French drug maker is the first divestment from liquidated fund Novalpina I, now managed by Berkeley Research Group
Ylva Hannestad joins GP’s client engagement around sustainability agenda